These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D; Dass R; Hettle R BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207 [TBL] [Abstract][Full Text] [Related]
6. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246 [TBL] [Abstract][Full Text] [Related]
7. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231 [No Abstract] [Full Text] [Related]
8. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J; Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286 [TBL] [Abstract][Full Text] [Related]
9. Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis. Jang JC; Jung YG; Choi J; Jung H; Ryoo S J Microbiol; 2017 Jun; 55(6):483-487. PubMed ID: 28429168 [TBL] [Abstract][Full Text] [Related]
10. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. Conradie F; Diacon AH; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Egizi E; Moreira J; Timm J; McHugh TD; Wills GH; Bateson A; Hunt R; Van Niekerk C; Li M; Olugbosi M; Spigelman M; N Engl J Med; 2020 Mar; 382(10):893-902. PubMed ID: 32130813 [TBL] [Abstract][Full Text] [Related]
12. First use of bedaquiline in a patient with XDR-TB in Singapore. Chua AP; Hoo GS; Chee CB; Wang YT BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26400590 [TBL] [Abstract][Full Text] [Related]
13. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. Yang JS; Kim KJ; Choi H; Lee SH Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700 [TBL] [Abstract][Full Text] [Related]
14. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified? Kunkel A; Furin J; Cohen T Lancet Infect Dis; 2017 Dec; 17(12):e429-e433. PubMed ID: 28533094 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Mbuagbaw L; Guglielmetti L; Hewison C; Bakare N; Bastard M; Caumes E; Fréchet-Jachym M; Robert J; Veziris N; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Schünemann HJ; Lienhardt C Emerg Infect Dis; 2019 May; 25(5):936-943. PubMed ID: 31002070 [TBL] [Abstract][Full Text] [Related]
16. Compassionate use of bedaquiline in the treatment of pulmonary XDR-TB. Danckers M; Lesko MB; Adamson R; Leibert E Int J Tuberc Lung Dis; 2014 Dec; 18(12):1522-3. PubMed ID: 25517823 [No Abstract] [Full Text] [Related]
17. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Olayanju O; Limberis J; Esmail A; Oelofse S; Gina P; Pietersen E; Fadul M; Warren R; Dheda K Eur Respir J; 2018 May; 51(5):. PubMed ID: 29700106 [TBL] [Abstract][Full Text] [Related]
18. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment. Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266 [TBL] [Abstract][Full Text] [Related]
19. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153 [TBL] [Abstract][Full Text] [Related]
20. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]